Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toru Tanaka

Showing results (231-240 of 265) with videos related to

Pageof 27
Sort By:
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|September 13, 2022
Home-measured pulse pressure is a predictor of cardiovascular disease in type 2 diabetes: The KAMOGAWA-HBP studyMaya Takegami, Emi Ushigome, Shinnosuke Hata, et al.
Experimental Cell Research|December 11, 2020
Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axisMinoru Inomata, Koichiro Kamio, Arata Azuma, et al.
Thoracic Cancer|February 26, 2020
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancerTeppei Sugano, Masahiro Seike, Yoshinobu Saito, et al.
Respiratory Medicine Case Reports|February 7, 2019
Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestationsJunichi Aoyama, Hiroki Hayashi, Chika Yajima, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 31, 2008
The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetesGoji Hasegawa, Shizuo Kajiyama, Toru Tanaka, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 15, 2022
Impact of sustained hypertension on new cardiovascular events in patients with type 2 diabetes: KAMOGAWA-HBP studyTakashi Yoshimura, Emi Ushigome, Shinnosuke Hata, et al.
Journal of Hypertension|August 19, 2022
Maximum home blood pressure and cardiovascular outcomes in patients with type 2 diabetes: KAMOGAWA-HBP studyShinnosuke Hata, Emi Ushigome, Takashi Yoshimura, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 11, 2023
Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP studyShinnosuke Hata, Emi Ushigome, Yukako Hosomi, et al.
Oxford Medical Case Reports|October 27, 2018
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravisTakehiro Tozuka, Teppei Sugano, Rintaro Noro, et al.
Journal of Diabetes Investigation|March 19, 2019
Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: The KAMOGAWA-HBP studyTakuro Okamura, Emi Ushigome, Nobuko Kitagawa, et al.
Pageof 27

Showing results (231-240 of 265) with videos related to

Sort By:
Pageof 27
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|September 13, 2022
Home-measured pulse pressure is a predictor of cardiovascular disease in type 2 diabetes: The KAMOGAWA-HBP studyMaya Takegami, Emi Ushigome, Shinnosuke Hata, et al.
Experimental Cell Research|December 11, 2020
Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axisMinoru Inomata, Koichiro Kamio, Arata Azuma, et al.
Thoracic Cancer|February 26, 2020
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancerTeppei Sugano, Masahiro Seike, Yoshinobu Saito, et al.
Respiratory Medicine Case Reports|February 7, 2019
Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestationsJunichi Aoyama, Hiroki Hayashi, Chika Yajima, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 31, 2008
The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetesGoji Hasegawa, Shizuo Kajiyama, Toru Tanaka, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|November 15, 2022
Impact of sustained hypertension on new cardiovascular events in patients with type 2 diabetes: KAMOGAWA-HBP studyTakashi Yoshimura, Emi Ushigome, Shinnosuke Hata, et al.
Journal of Hypertension|August 19, 2022
Maximum home blood pressure and cardiovascular outcomes in patients with type 2 diabetes: KAMOGAWA-HBP studyShinnosuke Hata, Emi Ushigome, Takashi Yoshimura, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 11, 2023
Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP studyShinnosuke Hata, Emi Ushigome, Yukako Hosomi, et al.
Oxford Medical Case Reports|October 27, 2018
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravisTakehiro Tozuka, Teppei Sugano, Rintaro Noro, et al.
Journal of Diabetes Investigation|March 19, 2019
Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: The KAMOGAWA-HBP studyTakuro Okamura, Emi Ushigome, Nobuko Kitagawa, et al.
Pageof 27